Cigna Q2 Earnings Raise 2026 Outlook

The Cigna Group (CI) reported stronger-than-expected Q2 earnings on July 30, 2026, and raised its full-year adjusted earnings outlook after broad growth in Evernorth Health Services and Cigna Healthcare. Management linked the results to specialty-drug demand and premium pricing actions.

Quarter Lifts Outlook

For the quarter ended June 30, 2026, Cigna reported total revenues of $71.7 billion, up 7.0% year over year. Adjusted income from operations, a non-GAAP measure, rose 6.0% to $2.1 billion, or $7.78 per share, exceeding consensus estimates of $7.58 to $7.60. GAAP net income was $1.7 billion, or $6.29 per share. The company raised its full-year adjusted income from operations outlook to at least $30.45 per share, $0.10 above prior guidance. The earnings release described the quarter as “reflecting solid operational performance across its diversified portfolio of businesses.”

Evernorth and Cigna Healthcare

Evernorth Health Services drove much of the revenue growth, reporting adjusted revenues of $61.5 billion, up about 6.0% year over year, with pretax adjusted earnings of $1.7 billion. Specialty and Care Services within Evernorth posted pretax adjusted earnings of $1.1 billion, a 22.0% increase from a year earlier. Pharmacy Benefit Services contributed $609 million in pretax adjusted earnings. Total pharmacy customers at quarter end were 118.2 million, down about 4.0% from December 31, 2025, reflecting expected client transitions and lower membership from some health-plan clients. The company cited this product mix—strong specialty and care-services margins alongside sizable pharmacy volumes—as a core driver of profit improvement.

Cigna Healthcare posted adjusted revenues of roughly $11.8 billion, up 9.0% to 10.0% year over year, with pretax adjusted earnings of $1.3 billion. The unit’s medical cost ratio rose to 84.5% from 83.2% in the prior-year quarter, partly due to larger prior-year risk-adjustment benefits in its Individual and Family Plans. Management attributed revenue growth mainly to premium-rate increases. Executives cited specialty-drug demand and pricing actions as reasons for confidence in raising full-year guidance despite higher medical costs.

Capital Returns and Six-Month Trends

For the six months ended June 30, 2026, consolidated revenue was $140.2 billion, up from $132.7 billion a year earlier. Net income rose to $3.3 billion from $2.9 billion. Basic earnings per share for the period were $6.31, with diluted EPS at $6.29. The board declared a cash dividend of $1.56 per share, payable September 23, 2026, to shareholders of record on September 8, 2026. The six-month gains in revenue and net income, along with the dividend, highlight the company’s ability to generate cash across its health-services and insurance operations while maintaining financial flexibility.